Gastroenterology
Volume 119, Issue 6 , Pages 1637-1648 , December 2000

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial

Received 20 December 1999 ,Accepted 19 July 2000.

References 

  1. Maddrey WC, Boitnott JK, Bedine MS, Weber FLJ, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–199
  2. Akriviadis EA, Steindel H, Pinto PC, Fong T-L, Kanel G, Reynolds TB, et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology. 1990;99:811–818
  3. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992;326:507–512
  4. Imperiale TF, McCullogh AJ. Do corticosteroids reduce mortality from alcoholic hepatitis?. Ann Intern Med. 1990;113:299–307
  5. Reynolds TB, Benhamou J-P, Blake J, Naccarato R, Orrego H. Treatment of acute alcoholic hepatitis. Gastroenterol Int. 1989;2:208–216
  6. Black M, Tavill AS. Corticosteroids in severe alcoholic hepatitis. Ann Intern Med. 1989;110:677–680
  7. Bird GLA, Sheron N, Goka AKJ, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med. 1990;112:917–920
  8. Khoruts A, Stahnke L, McClain CI, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991;13:267–276
  9. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology. 1993;18:576–580
  10. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology. 1993;18:41–46
  11. McClain CJ, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993;13:170–182
  12. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9:349–351
  13. Ohlinger W, Dinges HP, Zatloukal K, Mair S, Gollowitsch F, Denk H. Immunohistochemical detection of tumor necrosis factor-alpha, other cytokines and adhesion molecules in human livers with alcoholic hepatitis. Virchows Arch A Pathol Anat Histopathol. 1993;423:169–176
  14. McHutchison JG, Runyon BA, Draguesku JO, Cominelli F, Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis (abstr). Hepatology. 1991;14:96A
  15. Mandel GL. ARDS, neutrophils and pentoxifylline. Am Rev Respir Dis. 1988;138:1103–1105
  16. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet. 1989;2:1474–1477
  17. Doherty GM, Jensen CJ, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192–198
  18. Han J, Thompson B, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor for analysis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394
  19. Sarper R, Tarcan YA. An improved method of estimating the portal venous fraction of total hepatic blood flow from computerized radionuclide angiography. Radiology. 1983;147:559–562
  20. Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology. 1995;21:1304–1309
  21. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology. 1997;26:143–146
  22. Essani NA, Fisher MA, Farhood A, Manning AM, Smith CW, Jaescke H. Cytokine-induced hepatic intercellular adhesion molecule-1 (ICAM-1) mRNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. Hepatology. 1995;21:1632–1639
  23. Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, et al. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology. 1996;23:506–514
  24. Mawet E, Shiratori Y, Hikiba Y, Takada H, Yoshida H, Okano K, et al. Cytokineinduced neutrophil chemoattractant release from hepatocytes is modulated by Kupffer cells. Hepatology. 1996;23:353–358
  25. Schilling PJ, Murray JL, Markowitz AB. Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction. Cancer. 1992;69:256–260
  26. Goulis J, Akriviadis EA, Danielidis M, Xanthakis L. Pentoxifylline inhibits increased serum tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels and improves renal function in patients with hepatorenal syndrome (abstr). Hepatology. 1996;24:450A
  27. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987;34:50–97
  28. Yasui K, Ohta K, Kobayasi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med. 1996;124:891–893
  29. Wolchok JD. Treatment of Behçet disease with pentoxifylline (letter). Ann Intern Med. 1997;126:493
  30. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis: natural history and evaluation of prednisolone therapy. Ann Intern Med. 1971;74:311–321
  31. Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy: comparison of prednisolone with caloric supplements. Gastroenterology. 1978;74:169–173
  32. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:685–690
  33. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996;110:1847–1853
  34. Campra JL, Hamlin EM, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis: report of a controlled trial. Ann Intern Med. 1973;79:625–631
  35. DePew W, Boyer T, Omata M, Redeker AG, Reynolds TB. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology. 1980;78:524–529
  36. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut. 1995;37:113–118
  37. Rodriguez-Rodriguez E, Gonzalez-Reimers E, Santolaria-Fernandez F, Milena-Abril A, Rodriguez-Moreno F, Oramas-Rodriguez J, et al. Cytokine levels in acute alcoholic hepatitis: a sequential study. Drug Alcohol Depend. 1995;39:23–27
  38. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong F, Veech GA, et al. Plasma tumor necrosis factor-α predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res. 1990;14:255–259
  39. Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology. 1994;45:339–345
  40. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, et al. Phase I–II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 1991;78:1205–1211
  41. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Feber A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res. 1994;54:3436–3441

☆ No reprints available.

☆☆ Financial support for TNF measurements was kindly provided by Hoeschst-Roussel Pharmaceuticals Inc.

PII: S0016-5085(00)51183-4

Gastroenterology
Volume 119, Issue 6 , Pages 1637-1648 , December 2000

Article Tools

* Image Usage & Resolution